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Abstract
Maroteaux^Lamy syndrome (mucopolysaccharidosis type VI, MPS VI) is an autosomal recessive disorder due to the
deficiency of the lysosomal enzyme N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ASB). Mutation analysis in
Maroteaux^Lamy syndrome resulted in the identification of approximately 40 molecular defects underlying a great genetic
heterogeneity. Here we report five novel mutations in Italian subjects: S65F, P116H, R315Q, Q503X, P531R; each defect
was confirmed by restriction enzyme or amplification refractory mutation system (ARMS) analysis. We also performed a
three-dimensional (3-D) structure analysis of the alterations identified by us, and of an additional 22 point mutations
reported by other groups, in an attempt to draw helpful information about their possible effects on protein
conformation. ß 1999 Elsevier Science B.V. All rights reserved.
Keywords: Mucopolysaccharidosis type VI; Mutation analysis
1. Introduction
Mucopolysaccharidosis type VI (MPS VI), Maro-
teaux^Lamy syndrome, is a glycosaminoglycan stor-
age disorder caused by the de¢ciency of the lysoso-
mal enzyme arylsulfatase B (ASB, N-acetyl-
galactosamine-4-sulfatase, EC 3.1.6.12) that is re-
quired for degradation of glycosaminoglycans der-
matan sulfate and chondroitin sulfate [1]. A de¢-
ciency of this enzyme causes urinary excretion and
intralysosomal accumulation of large amounts of
partially degraded dermatan sulfate leading to varia-
ble clinical symptoms: according to the age of onset
and progression of symptoms, three forms of the
disease can be di¡erentiated (infantile or severe, ju-
venile or intermediate, and adult form or mild).
Arylsulfatase B and arylsulfatase A are the only
sulfatases for which the crystal structure has been
solved and re¢ned at 2.5^2.1 Aî resolution [2,3]. As
for all sulfatases, ASB was reported by sequence
alignment [4,5] to contain a CTPSR ‘common sulfa-
tase motif’ where the Cys 91 residue plays an impor-
tant role in enzyme function. In fact this residue has
been shown to undergo a post-translational modi¢-
0925-4439 / 99 / $ ^ see front matter ß 1999 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 9 8 ) 0 0 0 9 9 - 4
* Corresponding author. Fax: +39-81-746-3150;
E-mail : dinatale@cds.unina.it
BBADIS 61800 11-2-99 Cyaan Magenta Geel Zwart
Biochimica et Biophysica Acta 1453 (1999) 185^192
cation to 2-amino-3-oxopropionic acid [6] ; the sub-
sequent reaction scheme(s) for sulfate ester cleavage
has recently been proposed [2,7]. The conserved res-
idues that line the ASB active sites are Asp 53, Asp
54, Cys 91, Pro 93, Ser 94, Arg 95, Lys 145, His 147,
His 242, Asp 300 and Lys 318; moreover a metal ion
(Ca2) has been proposed to be involved in the active
site [2].
Isolation of the ASB cDNA [8,9] and character-
ization of the exon/intron structure of the ASB gene
[10] allowed analysis of the molecular basis of this
disease, leading to the identi¢cation of several ASB
gene mutant alleles [11^19]. The biochemical e¡ects
of the identi¢ed mutations on the ASB polypeptides
were studied by in vitro expression for few defects
[11,14,15,17].
In this study we report the identi¢cation of ¢ve
novel mutations in Italian patients with varying clin-
ical severities and their structural localization using a
3-D structural analysis.
2. Materials and methods
2.1. Patients
Fibroblasts of patients Mo., Br. and La. were ob-
tained from Prof. Gatti of the Gaslini Institute, Gen-
ova; lymphoblasts of patient Gu. were obtained
from Prof. Fois of the Pediatric Clinic, University
of Siena, and lymphoblasts of patient Ri. were
from Prof. Andria of the Department of Pediatrics,
University of Naples. Arylsulfatase B de¢ciency was
assessed by demonstration of severely decreased en-
zyme activity in patients’ cells. Classi¢cation of sub-
jects in severe, intermediate or mild forms (Table 1)
was from the above mentioned clinicians who fol-
lowed the criteria of Neufeld and Muenzer [1]. In
this classi¢cation, the severe form is characterized
by very early onset and severe progression of the
symptoms: facial dysmorphism, skeletal abnormal-
ities, compression of the spinal cord, corneal cloud-
ing, hepatosplenomegaly, mental retardation (patient
Gu. was diagnosed at age 14 months); the mild form
is characterized by the very late onset and absence of
mental retardation (patient Ri. was diagnosed at
7 years of age), while the intermediate form is in
the middle of such spectrum of phenotypes.
2.2. Genomic DNA extraction, PCR experiments and
SSCP analysis
Genomic DNA was obtained from patients’ ¢bro-
blasts and from normal controls as described [20].
For both cases, mutation screening was performed
using single-strand conformation polymorphism
(SSCP) analysis as previously reported [19]. Polymer-
ase chain reaction (PCR) conditions for ampli¢cation
of patients DNA were according to Isbrandt et al.
[15], except for exon 5, where ampli¢cation was ob-
tained using the following primers: ABE1 (5P-TCA-
GATAACGGAGGGCAGA-3P) and ABE2 (5P-GG-
TACCTGATGGTTTTCCA-3P).
2.3. DNA sequencing
PCR-ampli¢ed DNA fragments were sequenced
directly, without subcloning, by £uorescent dye ter-
minator cycle sequencing, and analysis was per-
formed on an automated DNA-Sequencer (Applied
Biosystems).
2.4. Restriction enzyme and ARMS analysis
After complete sequencing of the PCR products,
restriction enzyme analysis or ampli¢cation refrac-
tory mutation system (ARMS) analysis [21] were
done to con¢rm the authenticities of the novel muta-
tions. In parallel to patients’ samples, DNA from
Table 1
Mutations found in the ARSB gene of Italian MPS VI patients
Patients Phenotype Exon Mutation Polymorphism
exon Amino acid
change
Mo. Inter-
mediate
1 S65F 2 I114I (sil)
2 L124L(sil)
5 G324G (sil)
5 V358M
Gu. (+) Severe 2 P116H
Br. Inter-
mediate
5 R315Q
La. Inter-
mediate
8 Q503X 2 L124L (sil)
5 V358M
Ri. (+) Mild 8 P531R
(+): Consanguinity.
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Fig. 1. Identi¢cation of point mutations in ASB gene exons of ¢ve MPS VI patients. Sequencing diagrams covering positions of nu-
cleotide alterations are shown. The nucleotide sequence is given above the graphs; nucleotide alterations in comparison with the wild
type ASB cDNA are arrowed. Patient initials, mutation and nucleotide alteration are listed.
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10 normal subjects was also examined. Restriction
enzyme digestion was performed on mutations
P116H, R315Q and P531R. Enzymes were purchased
from New England Biolabs (Beverly, MA). Genomic
DNA samples were ampli¢ed by PCR and puri¢ed
by Agarose Gel DNA Extraction kit (Boehringer
Mannheim) or Qiagen gel extraction kit (Diagen)
as described by the manufacturer. After puri¢cation,
digestion was performed as recommended by the
manufacturer.
ARMS analysis was performed on mutations S65F
and Q503X using allele speci¢c primers. For S65F
mutation the following primers were used: mS65F
(mutant primer containing the mutant base at 3P
and a additional deliberate mismatch G/C three
bases from the 3P end: 5P-GCGCGTCCAGGTGC-
GGCGTGCGGATGCCGA-3P) or nS65F (normal
primer containing only the additional mismatch:
5P-GCGCGTCCAGGTGCGGCGTGCGGATGCC-
GG-3P) ; the common primer was AB92, as named by
Isbrandt et al. [15]. For Q503X mutation, primers
were the following: mQ503X (containing the mutant
base and a T/A mismatch three bases from the 3P
end: 5P-ACATCGTCACAAAGCTCCTGTCCCGC-
CAAT-3P) or nQ503X (containing only the T/A mis-
match: 5P-ACATCGTCACAAAGCTCCTGTCCC-
GCCAAC-3P) ; the common primer was AB68 [15].
All the reactions contained primers SAG1/SAG2 am-
plifying a fragment of 392 bp corresponding to exon
7 of heparin N-sulfamidase gene as internal control
[22].
2.5. Graphical analyses
All graphical analyses were run on a Silicon
Graphics Indigo2 workstation, using the package
INSIGHT II (Biosym Technologies). The co-ordi-
nates for the human lysosomal sulfatase (N-acetylga-
lactosamine-4-sulfatase) X-ray structure at 2.5 Aî res-
olution [2] were obtained from Protein Data Bank
(a) (1FSU) (Brookhaven National Laboratory, Up-
ton, NY).
3. Results
To identify possible exonic mutations in the ASB
gene of ¢ve Italian patients, the entire open reading
frame was PCR-ampli¢ed on eight DNA fragments,
each covering an exon and its £anking regions. The
obtained exons were screened by SSCP analysis to
identify fragments with anomalous patterns [19].
DNA sequence analysis was performed by direct £u-
orescent dye-terminator cycle sequencing as de-
scribed in Section 2. In all ¢ve cases the alterations
were shown to be homoallelic, although only two
patients were the outcome of a consanguineous mar-
riage (Table 1).
In patient Mo., SSCP alterations were found in
exons 1, 2 and 5 (Table 1). DNA sequencing showed
a homoallelic C to T transition at position 194,
which resulted in a Ser to Phe change at residue 65
(S65F; Fig. 1A). In addition to the disease-causing
mutation, in this patient, sequence analysis showed
the existence of several polymorphisms concerning
exon 2 (I114I and L124L) and exon 5 (G324G and
V358M). Of these, V358M was previously reported
to be a polymorphism [9,11]. In exon 2, the patient
was found to be homozygous for the silent T to C
transitions at nucleotides 342 and 370, in the third
base of a Ile codon at amino acid 114 and in the ¢rst
base of a Leu codon at amino acid 124, respectively.
In exon 5, a homoallelic silent A to G transition was
found at nucleotide 972 in the third base of a Gly
codon, at amino acid 324 (data not shown).
In patient Gu., the sequence of exon 2 revealed a
single base substitution, a C to A transversion at
nucleotide 347, which resulted in a Pro to His re-
Fig. 2. ARMS and restriction analysis of the identi¢ed mutations. (A,D) ARMS test for S65F and Q503X mutations. M is the molec-
ular marker 100 bp ladder. Lanes 1 and 2, normal control; lanes 3 and 4, patients. Lanes 1 and 3, the genomic DNA was ampli¢ed
by using the normal primer; lanes 2 and 4, the genomic DNA was ampli¢ed by using the mutant primer. All the reactions included
as common primer AB92 for S65F mutation, and AB68 for Q503X alteration; SAG1/SAG2 primers were used to amplify the internal
control fragment (see Section 2). On the bottom: a schematic representation of the ASB gene showing the localization of the primers
used in the ARMS analysis. (B,C,E) Restriction enzyme analyses for P116H, R315Q, P531R mutations. PCR ampli¢ed genomic DNA
fragments were digested as described in Section 2 and the products were separated on a 2% agarose gel. M, 100 bp DNA ladder.
Lane 1, normal control; lane 2, patient; lane 3, undigested samples.
C
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placement at residue 116 (P116H; Fig. 1B). A G to A
transition at nucleotide 944 of the exon 5 was found
in patient Br., which resulted in a Arg to Gln change
at residue 315 (R315Q; Fig. 1C). In patient La., a C
to T transition at nucleotide 1507 created a nonsense
mutation that changed CAG (Gln) to TAG (stop) at
codon 503 in exon 8 (Q503X; Fig. 1D). The patient
was also found to be homozygous for the polymor-
phisms L124L and V358M (Table 1). Finally, for
patient Ri., sequence analysis revealed a C to G
transversion at nucleotide 1592 which caused a Pro
to Arg substitution at residue 531 in exon 8 (P531R;
Fig. 1E).
Sequence analysis revealed that none of the ¢ve
mutant alleles identi¢ed here was found in 50 normal
ASB alleles from unrelated healthy subjects; more-
over, the Q503X results in a stop codon. These re-
sults suggest that the identi¢ed molecular alterations
are mutations causing functional defects in the en-
coded ASB polypeptides rather than polymorphisms.
The new mutations were con¢rmed by restriction en-
zyme or ARMS analyses, on PCR-ampli¢ed genomic
DNA (Fig. 2). As shown in Fig. 2A, ARMS analysis
performed using appropriate primers described in
Section 2 con¢rmed that patient Mo. was homoal-
lelic for the S65F mutation, since his exon 1 DNA
was ampli¢ed only with mutant primer mS65F.
ARMS test con¢rmed also that patient La. had a
homozygous condition for Q503X mutation (Fig.
2D). The P116H mutation caused, in the homoallelic
patient Gu., the disappearance of a restriction site
for Sau 96 I enzyme that in wild-type DNA cleaves
a 229 bp PCR product to 175 and 54 bp (Fig. 2B).
R315Q alteration in the homozygous subject Br.
abolishes a TaqI site whitin exon 5, leading, after
digestion, to 227 and 26 bp fragments instead of
179, 48 and 26 bp found in wild-type DNA (Fig.
2C). Finally, P531R mutation in the homoallelic pa-
tient Ri. destroys the ApaI resulting in a 380 bp frag-
ment, replacing the normal situation of 314 and 66
bp fragments (Fig. 2E).
All these ¢ve mutations, together with the other
two previously described by us (G302R, Q456X)
and with 22 point mutations reported by di¡erent
laboratories (L72Q, T92M, R95Q, L98P, C117R,
G137V, G144R, W146X, R152W, R160Q, R160X,
C192R, Y210C, L236P, R315X, S320R, L321P,
H393P, C405Y, L498P, Y513X, C521Y), were
graphically analysed as described in Section 2. Re-
sults of this analysis are shown in Fig. 3.
Fig. 3. Molecular model of N-acetylgalactosamine-4-sulfatase. The model shows the seven alterations found in Italian patients (tur-
quoise) and the other mutations analysed (blue). The active site is shown in green.
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4. Discussion
We report here ¢ve novel mutations in arylsulfa-
tase B gene: S65F, R315Q and Q503X associated to
intermediate phenotypes, P116H found in a severely
a¡ected patient and P531R associated with a mild
subject. We also report the identi¢cation of three
silent mutations in exons 2 and 5 (I114I, L124L,
G324G), but at this time we are not able to de¢ne
if these polymorphisms could have some e¡ect on
clinical phenotypes, as suggested for MPS I disease
[23]. It should be noted that all the ¢ve mutations
were found in homozygosity although only for two
subjects (Gu. and Ri., Table 1) consanguinity was
proven. For the other three patients, since it is un-
usual that a subject with a rare disease, such as MPS
VI occurring in less than 1:100 000 births, would be
homoallelic for a mutation, unless the mutant allele
was common or the patient was a product of a con-
sanguineous mating, this latter explanation is pre-
sumed possible.
None of the ¢ve alterations reported here involve
amino acids that are conserved between the eukary-
otic sulfatases aligned so far [4,5,8]. Nonetheless we
hypothesize that these amino acids may play a role in
enzyme’s structure and/or function. The missense
S65F mutation concerns an amino acid which may
be critical for enzyme function, since position 65 is
located in close proximity to the 53-Asp^Asp-54 di-
peptide involved in the active site. The substitution
of a polar amino acid (Ser) with a hydrophobic one
(Phe) could alter the contacts between the Asp resi-
due with the metal ion Ca2 [2]. For P116H muta-
tion, since it was reported that enzyme^substrate
contacts are made also by Pro116 [2], one can spec-
ulate that introduction of a positive charge in this
position could interfere with contacts formation.
Likewise, Arg315 substitution with Gln residue leads
to the loss of a positive charge in an important re-
gion involved both in substrate binding and metal
ion coordination. Accordingly, all these mutations
lead to severe or intermediate phenotypes.
The nonsense mutation Q503X results in the trans-
lation of a putative mutant enzyme lacking the last
30 amino acids. Because this truncation predicts the
loss a disul¢de bridge, it is possible that this alter-
ation may cause a major change of the overall struc-
ture of the enzyme resulting in a intermediate phe-
notype. Finally, mutation P531R concerns the third
amino acid from the C-terminus, thus it is unlikely
that it would result in a non-functional protein. Most
likely, since the C-terminal portion of ASB protein
has been shown to interact with a peculiar L-hairpin
structure presumably involved in mannose-6-phos-
phate acquisition [2], an alteration in this region
(i.e., P531R) could prevent the normal targeting of
the mutant protein. On the other hand, a putative
minimal amount of this altered protein could justify
the mild phenotype of patient Ri.
Graphical analysis of seven molecular defects iden-
ti¢ed by our group (Fig. 3, turquoise) ([19]; this
report) showed that no alteration occurred in the
active site. When this analysis was extended to 22
point mutations (Fig. 3, blue) identi¢ed by others
[11,12,15^17,24], only R95Q was shown to occur in
the active site, causing the loss of an H-bond be-
tween the NOH in Arg side chain and the hemiacetal
group. In conclusion, most of the mutations on ASB
gene seem to lead to structural impairment of the
protein folding, and, consequently, of the stability
of the mature form of the enzyme.
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